Malignant melanoma in the elderly: Different regional disease and poorer prognosis

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 538-543

  Macdonald, James B ^a   Dueck, Amylou C ^a   Gray, Richard J ^a   Wasif, Nabil ^a   Swanson, David L ^a   Sekulic, Aleksandar ^a   Pockaj, Barbara A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Elderly patients; Melanoma; Metastases

Indexed keywords

AGED; ARTICLE; DISEASE COURSE; FEMALE; GERIATRIC PATIENT; HEAD AND NECK CANCER; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS RATE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE;

EID: 84865287883     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.538     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60: 277-300.
2. Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res. 2010;20: 163-170.
3. Chao C, Martin RC, 2nd, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11: 259-264.
4. Rosenthal RA, Kavic SM. Assessment and management of the geriatric patient. Crit Care Med. 2004;32: S92-105.
5. Alexander HR, Turnbull AD, Salamone J, Keefe D, Melendez J. Upper abdominal cancer surgery in the very elderly. J Surg Oncol. 1991;47: 82-86.
6. MacKie RM. Malignant melanoma: clinical variants and prog-nostic indicators. Clin Exp Dermatol. 2000;25: 471-475.
7. MacKie RM, Hole D, Hunter JA, et al. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality,1979-94. The Scottish Melanoma Group. BMJ. 1997;315: 1117-1121.
8. Ramesh HS, Pope D, Gennari R, Audisio RA. Optimising sur-gical management of elderly cancer patients. World J Surg Oncol. 2005;3: 17.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the Ameri-can Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19: 3622-3634.
10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58: 71-96.
11. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11: 247-258.
12. Conway WC, Faries MB, Nicholl MB, et al. Age-related lym-phatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16: 1548-1552.
13. Caraco C, Marone U, Botti G, Celentano E, Lastoria S, Mozzillo N. Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy. Eur J Surg Oncol. 2006;32: 970-973.
14. Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nonder-matologist. Arch Dermatol. 2007;143: 488-494.
15. Liu W, Dowling JP, Murray WK, et al. Rate of growth in mela-nomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142: 1551-1558.
16. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cu-taneous melanoma. Cancer. 2008;112: 1795-1804.
17. Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM. Melanoma in the elderly patient: relevance of the aging immune system. Clin Dermatol. 2009;27: 537-544.
18. Tsai S, Balch C, Lange J. Epidemiology and treatment of mela-noma in elderly patients. Nat Rev Clin Oncol. 2010;7: 148-152.
19. Loggie B, Ronan SG, Bean J, Das Gupta TK. Invasive cutaneous melanoma in elderly patients. Arch Dermatol. 1991;127: 1188-1193.
20. Rivers JK, Kelly MC, Kopf AW, Welkovich B, Bart RS. Age and malignant melanoma: comparison of variables in different age-groups. J Am Acad Dermatol. 1989;21: 717-722.
21. Wiener DC, Argote-Greene LM, Ramesh H, Audisio RA, Jaklitsch MT. Choices in the management of asymptomatic lung nodules in the elderly. Surg Oncol. 2004;13: 239-248.
22. Adams J, Audisio RA, White M, Forman D. Age-related varia-tions in progression of cancer at diagnosis and completeness of cancer registry data. Surg Oncol. 2004;13: 175-179.
23. Kelly JW. Melanoma in the elderly--a neglected public health challenge. Med J Aust. 1998;169: 403-404.
24. Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. In-creasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol. 2005;125: 685-691.
25. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003;139: 282-288.
26. Testori A, Soteldo J, Sances D, et al. Cutaneous melanoma in the elderly. Melanoma Res. 2009;19: 125-134.
27. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in pa-tients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97: 1488-1498.
28. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamina-tion. Am J Clin Pathol. 2007;127: 380-384.
29. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
30. Stucky CC, Gray RJ, Dueck AC, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010;200: 770-774.
31. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node pos-itivity in melanoma. Cancer. 2007;109: 100-108.
32. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12: 587-596.
33. Kajiya K, Hirakawa S, Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol. 2006;169: 1496-1503.
34. Kajiya K, Sawane M, Huggenberger R, Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol. 2009;129: 1292-1298.
35. Murali R, Moncrieff MD, Hong J, et al. The prognostic value of tumor mitotic rate and other clinicopathologic factors in pa-tients with locoregional recurrences of melanoma. Ann Surg Oncol. 2010;17: 2992-2999.
36. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recur-rence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15: 1476-1484.
37. Reintgen DS, Cox C, Slingluff CL, Jr., Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg. 1992;28: 45-49.
38. Hohnheiser AM, Gefeller O, Gohl J, Schuler G, Hohenberger W, Merkel S. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg. 2010;35: 580-589.